Lansoprazol Vir

Lansoprazole, the active ingredient in Lansoprazol Vir, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑esophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Lansoprazol Vir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is indicated for several acid‑related gastrointestinal disorders.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief by decreasing acid exposure to the esophagus. - Peptic ulcer disease: promotes ulcer healing by suppressing gastric acid secretion. - Helicobacter pylori eradication regimens: enhances antibiotic efficacy when used as part of combination therapy. - Zollinger‑Ellison syndrome: controls hypergastrinemia‑driven acid hypersecretion.

Adverse reactions may occur with lansoprazole therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea or abdominal discomfort. - Flatulence or bloating. - Constipation: occasional.

Serious or Rare Side Effects: - Severe allergic reactions (e.g., Stevens‑Johnson syndrome, anaphylaxis). - Clostridioides difficile‑associated diarrhea. - Acute interstitial nephritis or renal impairment. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Bone fractures with long‑term high‑dose use.

Before initiating therapy, consider the following precautions.

- Assess renal and hepatic function: dose adjustment may be required in severe impairment. - Evaluate for known hypersensitivity to lansoprazole or other PPIs. - Use with caution in patients with osteoporosis: long‑term use may affect calcium absorption. - Monitor for potential vitamin B12 deficiency with prolonged therapy. - Consider drug‑interaction risk: review concomitant medications. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Lansoprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect; consider alternative therapy. - Atazanavir or other protease inhibitors: markedly decreased absorption; avoid co‑administration.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Methotrexate: reduced renal clearance; monitor serum levels. - Digoxin: increased serum concentration; observe for toxicity. - Iron or other pH‑dependent drugs: decreased absorption; separate dosing by at least 2 hours.